Evaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongation
- PMID: 29955466
- PMCID: PMC6007724
- DOI: 10.9740/mhc.2016.07.171
Evaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongation
Abstract
Introduction: Many psychotropic medications carry a risk of prolonging the QT interval and increasing the risk of developing Torsade de pointes (TdP). The goal of this study was to evaluate whether patients taking psychotropic agents with a known risk of TdP are being monitored at a community hospital through the use of electrocardiograms (EKGs).
Methods: This was a retrospective chart review of 100 adult patients-50 from general medicine floors and 50 from psychiatric units-who were taking at least one psychotropic agent with a known risk of TdP during hospitalization.
Results: The mean number of medications with QT-prolongation risk administered to the psychiatric and general medicine patients was 4.2 ± 1.7 and 3.9 ± 2.0, respectively (P = .7484). Thirty-two of the psychiatric patients (64%) and 48 of the general medicine patients (96%) received EKGs during their hospitalization (P < 0.0001). Of those newly starting the target medications, 58% (18 of 31) of the psychiatric patients and 71% (5 of 7) of the general medicine patients received a baseline EKG. The difference was not statistically significant (P = .6807). Overall, 8 patients (8%) had corrected QT (QTc) intervals >500 ms. Four had repeat EKGs performed, and none had medication changes made to decrease TdP risk.
Discussion: Many inpatients on psychiatric medications received multiple medications with a risk of TdP, but not all received monitoring through baseline or repeat EKGs when warranted. Patients with QTc intervals >500 ms were not appropriately managed to lower their risk of TdP. Pharmacists thus can help improve the monitoring and management of QT prolongation.
Keywords: EKG monitoring; QTc prolongation; Torsade de pointes; psychotropic medications.
Conflict of interest statement
Disclosures: The affiliations listed for Dr Girgis and Dr Liu are current positions, but the authors' work on this article was conducted separate from the current employer. Dr Maroney is a consultant for Janssen Pharmaceuticals.
Similar articles
-
QTc interval diurnal variations in patients treated with psychotropic medications: implications for the evaluation of drug induced QTc changes.Int Rev Psychiatry. 2022 Nov-Dec;34(7-8):689-692. doi: 10.1080/09540261.2022.2135985. Epub 2022 Oct 21. Int Rev Psychiatry. 2022. PMID: 36786118
-
QTc prolongation, torsades de pointes, and psychotropic medications.Psychosomatics. 2013 Jan-Feb;54(1):1-13. doi: 10.1016/j.psym.2012.11.001. Psychosomatics. 2013. PMID: 23295003 Review.
-
QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.Curr Med Res Opin. 2013 Dec;29(12):1719-26. doi: 10.1185/03007995.2013.840568. Epub 2013 Sep 23. Curr Med Res Opin. 2013. PMID: 24020938 Review.
-
Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.Ther Adv Cardiovasc Dis. 2021 Jan-Dec;15:17539447211058892. doi: 10.1177/17539447211058892. Ther Adv Cardiovasc Dis. 2021. PMID: 34841978 Free PMC article.
-
QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.J Clin Psychopharmacol. 2019 Jan/Feb;39(1):72-77. doi: 10.1097/JCP.0000000000000992. J Clin Psychopharmacol. 2019. PMID: 30531476
Cited by
-
A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population.Neuropsychiatr Dis Treat. 2018 Dec 24;15:105-114. doi: 10.2147/NDT.S186474. eCollection 2019. Neuropsychiatr Dis Treat. 2018. PMID: 30636876 Free PMC article. Review.
-
Use of Electrocardiogram Monitoring in Adult Patients Taking High-Risk QT Interval Prolonging Medicines in Clinical Practice: Systematic Review and Meta-analysis.Drug Saf. 2022 Oct;45(10):1037-1048. doi: 10.1007/s40264-022-01215-x. Epub 2022 Aug 10. Drug Saf. 2022. PMID: 35947343 Free PMC article.
References
-
- Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. . Prevention of Torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010; 121 8: 1047- 60. DOI: 10.1161/CIRCULATIONAHA.109.192704. PubMed PMID: 20142454. - DOI - PMC - PubMed
-
- Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, et al. . Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. Circulation. 2004; 110 17: 2721- 46. DOI: 10.1161/01.CIR.0000145144.56673.59. PubMed PMID: 15505110. - DOI - PubMed
-
- Woosley RL, Romero KA. . QTdrugs List [Internet]. Oro Valley (AZ): Azcert Inc [cited; 2014. Dec 2]. Available from: www.Crediblemeds.org
-
- Funk KA, Bostwick JR. . A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013; 47 10: 1330- 41. DOI: 10.1177/1060028013501994. PubMed PMID: 24259697. - DOI - PubMed
-
- Wenzel-Seifert K, Wittmann M, Haen E. . QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011; 108 41: 687- 93. DOI: 10.3238/arztebl.2011.0687. PubMed PMID: 22114630; PubMed Central PMCID: PMC3221427. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources